Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Altered G1 phase regulation in osteosarcoma

M S Benassi1, L Molendini, G Gamberi

  • 1Department of Musculo-skeletal Oncology, Rizzoli Orthopaedic Institute, Bologna, Italy. benassi@oncolab rizzoli.tizeta.it

International Journal of Cancer
|November 14, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MuSA: a Nextflow pipeline for deep, reproducible annotation and clinical ranking of genomic variants.

BMC bioinformatics·2026
Same author

A retrospective analysis of phase I and phase I/II investigator-initiated clinical trials conducted by the Swiss Group for Clinical Cancer Research (SAKK).

ESMO open·2025
Same author

SATURN: assessing the feasibility of utilising existing registries for real-world evidence data collection to meet patients, regulatory, health technology assessment and payer requirements.

Orphanet journal of rare diseases·2024
Same author

Project SATURN- a real-world evidence data collaboration with existing European datasets in Osteogenesis Imperfecta to support future therapies.

Orphanet journal of rare diseases·2024
Same author

Defining priorities in the transition from paediatric to adult healthcare for rare bone disease patients: a dialogic approach.

European journal of medical genetics·2023
Same author

IDH mutations in G2-3 conventional central bone chondrosarcoma: a mono institutional experience.

BMC cancer·2023

Cell cycle deregulation, specifically involving the retinoblastoma protein (pRb) and cyclin D1, is crucial in osteosarcoma (OS) development. pRb and cyclin D1 levels correlate with patient outcomes, suggesting their potential as prognostic markers for OS.

Area of Science:

  • Oncology
  • Cell Biology
  • Molecular Pathology

Background:

  • Cell cycle dysregulation drives abnormal cell proliferation and tumor formation.
  • The cyclin D/Cdk4 complex and retinoblastoma protein (pRb) are key regulators of the cell cycle.
  • Osteosarcoma (OS) is a primary bone cancer where cell cycle control is often disrupted.

Purpose of the Study:

  • To investigate the role of the cyclin D/Cdk4 complex and pRb in the pathogenesis of osteoblastic osteosarcoma (OS).
  • To correlate the expression levels of pRb, cyclin D1, and Cdk4 with clinical outcomes, including metastasis and relapse.

Main Methods:

  • Analysis of 40 osteosarcoma tumor samples using immunohistochemistry and immunoblotting.
  • Assessment of pRb, cyclin D1, and Cdk4 expression in tumor tissues and adjacent non-neoplastic tissues.

Related Experiment Videos

  • Co-immunoprecipitation to evaluate the formation of the cyclin D/Cdk4 complex.

    • Main Results:

    • Cdk4 was overexpressed in 80% of OS cases with uniform distribution in tumor cells.
    • Low levels of the active cyclin D/Cdk4 complex were observed.
    • 20 out of 40 OS cases showed negative or minimal immunostaining for active pRb.
    • pRb-negative patients had a significantly higher probability of relapse (p < 0.05).
    • High pRb/cyclin D1 levels correlated with functional pRb expression.

    Conclusions:

    • G1 phase deregulation is implicated in the formation and progression of osteosarcoma.
    • Expression levels of pRb and cyclin D1 serve as potential prognostic markers for osteosarcoma.
    • These findings highlight the importance of cell cycle regulators in OS development and patient prognosis.